Measures · D13 in 2016 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Medication Adherence for Hypertension (RAS antagonists)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- One of the most important ways you can manage your health is by taking your medication as directed. The plan, the doctor, and the member can work together to find ways to help the member take their medication as directed. Percent of plan members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. (“Blood pressure medication” means an ACE (angiotensin converting enzyme) inhibitor, an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.)
- How it's calculated
- This measure is defined as the percent of Medicare Part D beneficiaries 18 years and older that adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or direct renin inhibitor medications]. This percentage is calculated as the number of member-years of enrolled beneficiaries 18 years and older with a proportion of days covered (PDC) at 80 percent or over for RAS antagonist medications during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 18 years and older with at least two fills of either the same medication or medications in the drug class during the measurement period (denominator). The PDC is the percent of days in the measurement period “covered” by prescription claims for the same medication or another in its therapeutic category. Beneficiaries with ESRD coverage dates, as reported in the Medicare Enrollment Database (EDB), anytime during the measurement period are excluded. Beneficiaries are only included in the measure calculation if the first fill of their medication occurs at least 91 days before the end of the enrollment period. The Part D Medication Adherence measure is adapted from the Medication Adherence- Proportion of Days Covered measure that was developed and endorsed by the Pharmacy Quality Alliance (PQA). The PDC Adherence measures are also endorsed by the National Quality Forum (NQF). See the medication list for this measure. The Part D Medication Adherence rate is calculated using the National Drug Code (NDC) list and obsolete NDC date 2014 methodology maintained by the PQA. The complete NDC list will be posted along with these technical notes. For the 2016 Star Ratings, NDCs with obsolete dates will be included in the measure calculation if their obsolete dates as reported by PQA are within the period of measurement (measurement year) or within six months prior to the beginning of the measurement year.
- Data source
- Prescription Drug Event (PDE) data; Medicare Enrollment Database (EDB) File; The data for this measure come from PDE data files submitted by drug plans to Medicare for January 1, 2014-December 31, 2014 by June 30, 2015. Only final action PDE claims are used to calculate the patient safety measures. PDE claims are limited to members who received at least two prescriptions for RAS antagonist medication(s). PDE adjustments made post-reconciliation were not reflected in this measure.
- Measurement period
- 01/01/2014 - 12/31/2014
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- —
- In improvement measure
- Yes
- Used in CAI
- —
- Exclusions
Show
Contracts with 30 or fewer enrolled member-years (in the denominator)- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the medication or NDC lists, are excluded from CMS analyses. Also, the member-years of enrollment adjustment is made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the spell level, and inclusion in the measure is determined separately for each spell – i.e., to be included for a given spell, the beneficiary must meet the initial inclusion criteria for the measure during that spell. The measure is weighted based on the total number of member years for each spell in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three month spell, disenrolled for a six month spell, reenrolled for a three month spell, and meets the measure criteria during each enrollment spell, s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12). The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the Medi-Span generic ingredient name. The calculation also adjusts for Part D beneficiaries’ stays in inpatient (IP) settings, hospice enrollments, and stays in skilled nursing facilities (SNFs). The SNF adjustment only applies to PDPs because SNF data are not currently available for MA- PDs. When available, beneficiary death date from the Common Medicare Environment (CME) is the end date of a beneficiary’s measurement period. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculations.
From the 2016 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 85 | +1 |
| 3★ | MA-PD | 88 | 89 | +1 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 93 | 94 | +1 |
| 2★ | PDP | 87 | 88 | +1 |
| 3★ | PDP | 89 | 90 | +1 |
| 4★ | PDP | 90 | 91 | +1 |
| 5★ | PDP | 92 | 92 | 0 |
2016 star distribution
Not rated: Plan too new to be measured (102); No data available (31); Plan not required to report measure (12); Not enough data available (11)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 93 % | >= 93 % |
| 2027 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2026 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2026 | PDP | < 88 % | >= 88 % to < 90 % | >= 90 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2025 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2025 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2024 | MA-PD | < 82 % | >= 82 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2024 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 94 % | >= 94 % |
| 2023 | MA-PD | < 78 % | >= 78 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2023 | PDP | < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 96 % | >= 96 % |
| 2022 | MA-PD | < 74 % | >= 74 % to < 82 % | >= 82 % to < 87 % | >= 87 % to < 90 % | >= 90 % |
| 2022 | PDP | < 85 % | >= 85 % to < 88 % | >= 88 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2021 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 87 % | >= 87 % to < 89 % | >= 89 % |
| 2021 | PDP | < 84 % | >= 84 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2020 | MA-PD | < 80% | ? 80% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2020 | PDP | < 83% | ? 83% to < 85% | ? 85% to < 88% | ? 88% to < 90% | ? 90% |
| 2019 | MA-PD | < 79% | ? 79% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2019 | PDP | < 84% | ? 84% to < 86% | ? 86% to < 87% | ? 87% to < 89% | ? 89% |
| 2018 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2018 | PDP | < 78% | ? 78% to < 83% | ? 83% to < 86% | ? 86% to < 89% | ? 89% |
| 2017 | MA-PD | < 71% | ? 71% to < 75% | ? 75% to < 79% | ? 79% to < 83% | ? 83% |
| 2017 | PDP | < 77% | ? 77% to < 80% | ? 80% to < 83% | ? 83% to < 85% | ? 85% |
| 2016 | MA-PD | < 58% | ? 58% to < 73% | ? 73% to < 77% | ? 77% to < 81% | ? 81% |
| 2016 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2015 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 85% | ? 85% |
| 2015 | PDP | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 84% | ? 84% |
Lowest-scoring contracts, 2016
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| H8266 Constellation Health, Llc. | Constellation Health, LLC. | — | 34 | 1 | — | 43 | 0% |
| S2505 WINDSOR HEALTH PLAN, INC. | WellCare Health Plans, Inc. | — | 70 | 1 | 0 | 12 | 0% |
| H9122 ALPHACARE OF NEW YORK, INC. | Magellan Health, Inc. | — | 61 | 2 | — | 16 | 0% |
| H3071 Clear Spring Health | Group 1001 | — | 62 | 2 | — | 15 | 0% |
| H3337 LIBERTY HEALTH ADVANTAGE, INC. | Liberty Health Advantage, Inc. | — | 63 | 2 | +1 | 14 | 1% |
| H1903 WELLCARE OF LOUISIANA, INC. | WellCare Health Plans, Inc. | — | 64 | 2 | +1 | 13 | 1% |
| H0490 Molina Healthcare Of Ohio, Inc. | Molina Healthcare, Inc., | — | 65 | 2 | +1 | 12 | 1% |
| H6623 MARICOPA COUNTY SPECIAL HEALTH CARE DISTRICT | MARICOPA COUNTY SPECIAL HEALTH CARE DISTRICT | — | 65 | 2 | — | 12 | 1% |
| H1112 Wellcare | Centene Corporation | 25,885 | 66 | 2 | +1 | 11 | 2% |
| H9915 Medstar Family Choice, Inc. | Medstar Health, Inc. | — | 66 | 2 | +1 | 11 | 2% |
| S7694 Elixir Insurance | Rite Aid Corporation | — | 73 | 1 | 0 | 9 | 2% |
| H5475 Wellcare | Centene Corporation | 18,951 | 67 | 2 | +1 | 10 | 2% |
| H8130 Molina Healthcare of Florida | Molina Healthcare, Inc., | — | 68 | 2 | +1 | 9 | 2% |
| H5698 WINDSOR HEALTH PLAN, INC. | WellCare Health Plans, Inc. | — | 68 | 2 | +1 | 9 | 2% |
| H3708 American Health Advantage of Oklahoma | Mitchell Family Office | 549 | 68 | 2 | −3 | 9 | 2% |
| H4011 MMM HEALTHCARE, LLC. | InnovaCare Inc. | — | 69 | 2 | +1 | 8 | 3% |
| H0913 Wellcare | Centene Corporation | 12,667 | 69 | 2 | +1 | 8 | 3% |
| H5587 Blue Cross Blue Shield of Arizona Health Choice | Blue Cross Blue Shield of Arizona | 8,603 | 69 | 2 | +1 | 8 | 3% |
| R9896 CARE IMPROVEMENT PLUS SOUTH CENTRAL INSURANCE CO. | UnitedHealth Group, Inc. | — | 69 | 2 | +1 | 8 | 3% |
| H9190 Gateway Health Plan Of Ohio, Inc. | Gateway Health Plan, LP | — | 69 | 2 | — | 8 | 3% |
| H5294 Wellcare | Centene Corporation | 16,255 | 69 | 2 | +1 | 8 | 3% |
| H0908 Wellcare | Centene Corporation | 8,453 | 69 | 2 | +1 | 8 | 3% |
| S1140 Highmark Blue Cross Blue Shield or Highmark Blue Shield | Highmark Health | 3,185 | 74 | 1 | −1 | 8 | 4% |
| S2874 Humana | Humana Inc. | — | 74 | 1 | 0 | 8 | 4% |
| H5786 MERIDIAN HEALTH PLAN OF IOWA, INC. | Caidan Enterprises, Inc. | — | 70 | 2 | — | 7 | 5% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2025 – 12/31/2025 | 3 | Prescription Drug Events |
| 2026 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2024 – 12/31/2024 | 3 | Prescription Drug Events |
| 2025 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2023 – 12/31/2023 | 3 | Prescription Drug Events |
| 2024 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2022 – 12/31/2022 | 3 | Prescription Drug Events |
| 2023 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2021 – 12/31/2021 | 3 | Prescription Drug Events |
| 2022 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2018 – 12/31/2018 | 3 | Prescription Drug Events |
| 2019 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2017 – 12/31/2017 | 3 | Prescription Drug Events |
| 2018 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2016 – 12/31/2016 | 3 | Prescription Drug Events |
| 2017 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2015 - 12/31/2015 | 3 | Prescription Drug Events |
| 2016 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2014 - 12/31/2014 | 3 | Prescription Drug Events |
| 2015 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2013 - 12/31/2013 | 3 | Prescription Drug Events |